Variable | Total (N = 58) |
Age at diagnosis (years)—mean ± SD (minimum - maximum) | 41.85 ± 6.38 (28.00 - 52.00) |
Age at diagnosis—n (%) 29 - 35 years 36 - 40 years 41 - 45 years 46 - 50 years |
13 (22.4) 11 (19.0) 18 (31.0) 16 (27.6) |
Tumor size—n (%) T1 T2 T3 T4 INO |
24 (41.4) 22 (37.9) 7 (12.1) 3 (5.2) 2 (3,4) |
Lymph node involvement—n (%) | 23 (39.7) |
Hormone receptors—n (%) | 37 (63.8) |
HER2 hyperexpressed—n (%) | 6 (10.3) |
Type of surgery—n (%) Sectorectomy Mastectomy without reconstruction Mastectomy with reconstruction INO |
23 (39.7) 3 (5.2) 30 (51.7) 2 (3.4) |
Chemotherapy—n (%) Geral Adjuvant chemotherapy Neoadjuvant chemotherapy |
48 (82.8) 24 (41.4) 25 (43.1) |
Radiotherapy—n (%) | 39 (67.2) |
Hormone therapy—n (%) Tamoxifen Aromatase inhibitor |
33 (56.9) 5 (8.6) |